GLP-1 S

GLP-1 S is a synthetic analog of human glucagon-like peptide-1 (GLP-1), engineered with a C18 fatty diacid moiety attached via a linker to a modified GLP-1 backbone. This structural modification enables albumin binding, dramatically extending the half-life compared to native GLP-1 and supporting once-weekly dosing paradigms in research models. The peptide acts as a full agonist at the GLP-1 receptor, a class B G protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, and peripheral tissues. GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces food intake through central appetite-regulating circuits. These pleiotropic effects have made GLP-1 receptor agonists a major focus of metabolic research, particularly in the context of type 2 diabetes, obesity, non-alcoholic steatohepatitis (NASH), and cardiovascular disease. In laboratory settings, GLP-1 S is used to investigate receptor binding kinetics, downstream cAMP signaling, beta-cell function, and the neurobiological basis of appetite suppression. Its high receptor selectivity and extended pharmacokinetic profile make it a valuable tool for both in vitro assays and in vivo preclinical models requiring sustained GLP-1 receptor engagement.